A phase II study (NCT04580498), enrolling 107 patients, found that SHR-1701, a PD-L1/TGF-β antibody, is safe and effective for unresectable stage III NSCLC [62]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.